| [Fire Fighting] Wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Use agent most appropriate to extinguish fire. | |
| [Ingestion] Seek medical attention. If individual is drowsy or unconscious, do not give anything by mouth; place individual on the left side with the head down. Contact a physician, medical facility, or poison control center for advice about whether to induce vomiting. If possible, do not leave individual unattended. | |
| [Inhalation] If symptoms develop, move individual away from exposure and into fresh air. If symptoms persist, seek medical attention. If breathing is difficult, administer oxygen. Keep person warm and quiet; seek immediate medical attention. | |
| [Skin] Naloxone has a poor bioavailability when given orally, thus systemic adverse effects would be limited and gastrointestinal decontamination is rarely needed. See recommendations in the parenteral exposure section for treatment information. | |
| [Eyes] If symptoms develop, immediately move individual away from exposure and into fresh air. Flush eyes gently with water for at least 15 minutes while holding eyelids apart; seek immediate medical attention. | |
| [Storage] Protect from excessive light.Should be protected from excessive moisture and exposure to air.Should be stored below 30C. | |
| [Handling] All chemicals should be considered hazardous. Avoid direct physical contact. Use appropriate, approved safety equipment. Untrained individuals should not handle this chemical or its container. Handling should occur in a chemical fume hood. | |
| [Inhalation] Increased respiratory rate may be seen with large doses. Pulmonary edema has been noted in a few cases of therapeutic use. | |
| [Personal Protection] Chemical splash goggles in compliance with OSHA regulations are advised; however, OSHA regulations also permit other type safety glasses. Whre chemical resistant gloves. To prevent repeated or prolonged skin contact, wear impervious clothing and boots. | |
| [Respirators] Use NIOSH/MSHA approved respirator appropriate for exposure of concern. | |
| [Exposure Effects] With therapeutic use - seizures have been rarely seen with therapeutic use. Memory impairment has been reported in high dose therapy. Pregnancy Category B <br>No data were available to assess the teratogenic potential of this agent. <br>Naloxone is not known to produce adverse neonatal effects other than the possible precipitation of withdrawal symptoms in narcotic addicted mothers and their infants. Naloxone is clearly the drug of choice over nalorphine to reverse respiratory depression in the neonate. | |
| [Appearance] Crystals from ethyl acetate. | |
| [Solubility in water] Insoluble | |
| [Melting Point] 184 | |
| [pKa/pKb] 7.39 (pKb) | |
| [Usage] Medication. | |
| [Product Name] (5alpha)-3,14-Dihydroxy-17-prop-2-en-1-yl-4,5-epoxymorphinan-6-one | |
| [Synonyms] 17-Allyl-4,5alpha-epoxy-3,14-dihydroxymorphinan-6-one 1-n-Allyl-14-Hydroxynordihydromorphinone 1-n-Allyl-7,8-dihydro-14-hydroxynormorphinone n-Allyl-Noroxymorphone | |
| [CAS] 465-65-6 | |
| [Formula] C19H21NO4 | |
| [Molecular Weight] 327.38 | |
| [EINECS] 207-365-7 | |
| [RTECS] QD2260000 | |
| [RTECS Class] Drug; Mutagen; Reproductive Effector | |
| [Merck] 12,6449 | |
| [Beilstein/Gmelin] 1089071 | |
| [Small spills/leaks] Evacuate area and ventilate. Wear protective equipment. If required, use an inert absrobent. Sweep up and place in an appropriate container for disposal. Wash contaminated surfaces. | |
| [Stability] Not particularly hygroscopic; can oxidize; relatively stable in heat hydrochloride. | |
| [Incompatibilities] Strong oxidizing agents. |
Print